Filgotinib for treating moderate to severe rheumatoid arthritis – guidance (TA676)

NICE recommends filgotinib for moderate to severe RA in adults if specific criteria met. This follows clinical trial data showing filgotinib with DMARDs is more effective than with methotrexate alone or with adalumimab for RA that has not responded to 2 or more DMARDs.

Source:

National Institute for Health and Care Excellence